Tesofensine is a synthetic small molecule that acts as a triple monoamine reuptake inhibitor. It prevents the reabsorption of serotonin, dopamine, and norepinephrine, leading to significant appetite suppression and weight loss.

Is Tesofensine a peptide?

No, while often discussed alongside peptides in research communities (sometimes referred to as the "Tesofensine peptide"), it is structurally a small molecule. It does not consist of amino acid chains like true peptides.

What are the main Tesofensine benefits?

The primary Tesofensine benefits include extreme appetite suppression, increased resting energy expenditure, and significant reductions in body weight. It also shows potential for reversing dopamine deficits associated with obesity [Hansen HH et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23932919/).

What are the common Tesofensine side effects?

Common Tesofensine side effects include dry mouth, insomnia, nausea, and elevated heart rate. Because of its effect on heart rate, researchers have studied co-administering it with beta-blockers like metoprolol [NCT03488719](https://clinicaltrials.gov/study/NCT03488719).

Is Tesofensine FDA approved?

No, Tesofensine is currently not approved by the FDA for human use. It remains an investigational compound restricted to research and clinical trial settings.

How is Tesofensine administered in research?

In clinical trials, Tesofensine has primarily been administered orally as a daily capsule. However, in some experimental research settings, subcutaneous injection routes are also explored.

Tesofensine

Explore Tesofensine, a potent small molecule researched for extreme appetite suppression and weight loss. Discover Tesofensine benefits and side effects.

Research Onlyweight lossnootropicappetite suppressionsmall molecule

Last updated: 2026-04-03

Administration: subcutaneous
Origin: Synthetic (Small Molecule)

Overview

Tesofensine is a potent synthetic small molecule originally developed for neurodegenerative diseases but now heavily researched for its profound weight-loss properties. Functioning as a triple monoamine reuptake inhibitor, it prevents the reabsorption of serotonin, norepinephrine, and dopamine in the brain. This unique mechanism leads to significant appetite suppression and increased energy expenditure. While sometimes colloquially grouped with peptides as the "Tesofensine peptide" in research communities, it is strictly a small molecule that offers compelling insights into the pharmacological management of severe obesity and metabolic disorders.

Potential Benefits

Profound Weight Loss: Clinical trials demonstrate significant reductions in body weight, often outperforming other anti-obesity medications Doggrell SA, 2009.
Extreme Appetite Suppression: It reduces hunger by modulating dopamine and serotonin pathways, specifically silencing GABAergic hypothalamic neurons Perez CI et al., 2024.
Increased Energy Expenditure: Research indicates it elevates resting metabolic rate and promotes fat oxidation Bello NT, 2009.
Reversal of Dopamine Deficits: Studies in diet-induced obese models show it restores low forebrain dopamine levels, potentially reducing food-seeking behavior Hansen HH et al., 2013.
Potential Neuroprotective Effects: Originally tested in Parkinson's and Alzheimer's patients, it shows mild cognitive and motor function benefits Rascol O et al., 2008.

Side Effects

Common side effects:

Dry mouth and altered taste sensation
Insomnia or sleep architecture disturbances
Elevated resting heart rate (tachycardia)
Nausea or mild gastrointestinal distress
Mild anxiety, restlessness, or jitteriness

Rare or serious side effects:

Significant increases in systemic blood pressure
Severe psychiatric reactions including depression or agitation
Cardiovascular events in predisposed or high-risk individuals
Potential for monoamine toxicity at supratherapeutic doses

Tesofensine is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.

Mechanism of Action

Triple monoamine reuptake inhibition drives the primary pharmacological action of Tesofensine. By blocking the presynaptic reuptake transporters for serotonin, dopamine, and norepinephrine, it significantly increases the synaptic concentrations of these crucial neurotransmitters. This elevated neurotransmitter presence indirectly stimulates alpha-1 adrenoceptor and dopamine D1 receptor pathways, which are critical for regulating satiety and energy balance Axel AM et al., 2010.

Hypothalamic modulation is the downstream result of this neurotransmitter surge, leading to profound appetite suppression. Recent studies reveal that Tesofensine actively silences GABAergic neurons in the lateral hypothalamus, a region heavily involved in feeding behavior Perez CI et al., 2024. Furthermore, by reversing low forebrain dopamine levels typically seen in obesity, it diminishes the reward-seeking drive associated with hyperpalatable foods Hansen HH et al., 2013.

Origin & History

Initial discovery and development of Tesofensine (originally designated NS 2330) was spearheaded by NeuroSearch, aiming to treat neurodegenerative conditions like Parkinson's and Alzheimer's disease. Early Phase 2 clinical trials evaluated its efficacy for motor fluctuations and cognitive decline Rascol O et al., 2008. While it showed limited success for these primary endpoints, researchers noted a consistent, significant side effect: unintended, substantial weight loss among participants Astrup A et al., 2008.

Pivoting to obesity research, subsequent trials focused entirely on its metabolic and appetite-suppressing properties. To mitigate cardiovascular side effects like elevated heart rate, recent clinical developments have paired Tesofensine with metoprolol under the name Tesomet, targeting rare conditions like Prader-Willi Syndrome NCT03149445. Currently, Tesofensine remains an investigational compound and holds a research-only approval status, pending further large-scale safety evaluations by regulatory bodies.